| 1. |
- Birgegård, Gunnar, 1944-, et al.
(author)
-
Serum ferritin in the regulation of iron therapy in blood donors
- 1980
-
In: Vox Sanguinis. - 0042-9007 .- 1423-0410. ; 38:1, s. 29-35
-
Journal article (peer-reviewed)abstract
- 12 regular blood donors were selected on the basis of subnormal serum ferritin levels as a criterion for iron deficiency. It was found that all had high transferrin levels but only 5 had subnormal serum iron or transferrin saturation. The donors were given oral iron therapy in a dose of 2,800 mg between each phlebotomy, and the donation interval was standardized to 8 weeks. Test samples were collected every 4th week. After an initial rise in ferritin during the first 2 months, 6 of the donors again had subnormal serum ferritin levels, and the iron dose was therefore doubled after 32 weeks. Following this, all subjects taking the higher dose had normal ferritin values and stainable marrow iron was found at the end of the study, after 92 weeks. 3 subjects did not take the higher dose, had no raised serum ferritin level or stainable hemosiderin. It is concluded that serum ferritin estimation can be used to monitor the therapy in blood donors so that a satisfactory amount of iron is stored.
|
|
| 2. |
- Hammar, L, et al.
(author)
-
Lewis phenotype of erythrocytes and Leb-active glycolipid in serum of pregnant women
- 1981
-
In: Vox Sanguinis. - 1423-0410. ; 40:1, s. 27-33
-
Journal article (peer-reviewed)abstract
- In an attempt to provide an explanation for the previously reported effect of pregnancy on the Lewis phenotype of erythrocytes, the level of Leb-active glycolipid in serum was compared with the reactions of erythrocytes, using samples obtained from 73 nonpregnant women, 74 women at the time of delivery, and 2 women at weekly intervals during their pregnancy. In this Swedish population, the frequency of the Le(a--b-) blood group increased from 11% in nonpregnant women to 36% in women at the time of delivery. Among Le(a--b+) women of all ABO groups, those who were A1 most often became (Leb-) during pregnancy. The change in phenotype occurred as early as the 24th week of gestation; the Leb antigen was again detectable within 6 weeks after delivery. The concentration of Leb glycolipid in serum, as measured by radioimmunoassay, decreased only slightly during pregnancy. The repartition of glycolipids, secondary to the increased ratio of lipoprotein to red cell mass that occurs during pregnancy, may account for the relative lack of Lewis glycolipid on erythrocytes.
|
|
| 3. |
- Messeter, L, et al.
(author)
-
Immunochemical characterization of a monoclonal anti-Leb blood grouping reagent
- 1984
-
In: Vox Sanguinis. - 1423-0410. ; 46:2, s. 66-74
-
Journal article (peer-reviewed)abstract
- A haemagglutinating monoclonal anti-LebL antibody has been obtained from a mouse-mouse hybridoma after immunization with the Leb-active oligosaccharide lacto-N-difucohexaose I, coupled to edestin. Of 13 other antibodies obtained, one was able to agglutinate enzyme-treated erythrocytes of all ABO groups and three more were considered to be anti-LebH haemagglutinins. The remaining nine antibodies did not agglutinate red cells. The specificity of the stronger of the anti-LebL haemagglutinins was examined by studying its binding to a number of glycoconjugates and oligosaccharides.
|
|
| 4. |
- Messeter, L, et al.
(author)
-
Mouse monoclonal antibodies with anti-A, anti-B and anti-A,B specificities; some superior to human polyclonal ABO reagents
- 1984
-
In: Vox Sanguinis. - 1423-0410. ; 46:4, s. 185-194
-
Journal article (peer-reviewed)abstract
- A series of fusions using mouse myeloma cells and spleen cells from mice immunized with blood group substances or human red cells was performed with the aim of obtaining ABO antibodies suitable for routine blood grouping. Seven strongly agglutinating antibodies against antigens in the ABO system were obtained from 18 fusions. These antibodies were tested extensively in manual and automated routines, and six of them were found to be as good as or better than commercial polyclonal test sera of human origin.
|
|
